Screener
Sutro Biopharma STRO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue - current | 9,399 | 10,562 |
| Operating lease liability - current | 7,600 | 7,783 |
| Accrued expenses and other current liabilities | 42,973 | 34,581 |
| Total current liabilities | 70,811 | 75,133 |
| Deferred revenue - non-current | 1,233 | 2,028 |
| Operating lease liability - non-current | 6,032 | 7,891 |
| Deferred royalty obligation related to the sale of future royalties | 229,105 | 219,536 |
| Other non-current liabilities | 1,694 | 1,694 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's total current liabilities?
- Sutro Biopharma (STRO) reported total current liabilities of $70.81M in Q1 2026.
- How has Sutro Biopharma's total current liabilities changed year-over-year?
- Sutro Biopharma's total current liabilities decreased by 46.8% year-over-year, from $133.05M to $70.81M.
- What is the long-term trend for Sutro Biopharma's total current liabilities?
- Over 5 years (2020 to 2025), Sutro Biopharma's total current liabilities has grown at a 20.5% compound annual growth rate (CAGR), from $29.6M to $75.13M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Sutro Biopharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude